-+ 0.00%
-+ 0.00%
-+ 0.00%

BridgeBio Oncology Therapeutics COO Idan Elmelech files initial beneficial ownership statement

PUBT·04/30/2026 20:31:18
Listen to the news
BridgeBio Oncology Therapeutics COO Idan Elmelech files initial beneficial ownership statement
  • BridgeBio Oncology Therapeutics COO, principal financial officer Idan Elmelech filed Form 3 reporting 14,838 shares of common stock.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-197346), on April 30, 2026, and is solely responsible for the information contained therein.